CClinicalTrials.gg
RecruitingNCT06853366FC-LUTS-TCAUpdated Feb 28, 2025

Validation of the Short Form of the "Lower Urinary Tract Symptoms Treatment Constraints Assessment" Questionnaire

An observational study in Urologic Disorders, sponsored by Centre Hospitalier de Saint-Denis. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Centre Hospitalier de Saint-Denis · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
242
Ages
18 Years and older
Sex
All
01

Study summary

For many years, the evaluation of treatments has been a central issue in patient care. The various domains assessed have gradually evolved over time, ranging from satisfaction, improvement and quality of life, to the more recent introduction of the Patient Reported Outcome Measure (PROM). These questionnaires or measurement scales (PROMs) focus assessment on the patient and his or her direct experience. Statistical validation of numerous assessment tools has made it possible to quantify objectively many areas of assessment that were initially linked to the patient's feelings, and therefore to their subjectivity. Thus, improvement, quality of life, patient expectations and goal attainment have been the preferred areas for the development of these PROMs.

However, certain areas have been sidelined in the creation of these tools. For example, the constraint of care or the side effects or negative effects of care have not been studied through specific means of evaluation.

In response to this shortcoming, we have developed a questionnaire specifically designed for neuro-urological treatments in a neurological patient population.

The LUTS-TCA (Lower Urinary Tract Symptoms Treatment Constraints Assessment) was developed in French and statistically validated in 2019.

The aim of the study is to create a short form of the LUTS TCA in French, in a population of neurological patients.

This short form, which would be easier to use and interpret, would simplify its use in everyday practice. Indeed, a large majority of neuro-urology patients suffer from neurodegenerative or progressive pathologies, marked by significant and disabling physical and psychological fatigue symptoms. Long-form questionnaires, or the addition of multiple assessment questionnaires during a single visit to the department, make overall assessment more complex.

In addition, this short-form questionnaire is presented in a slightly different form to the long-form version, showing several domains of constraint (physical, social, psychological and care system). This classification should simplify the interpretation and understanding of care constraint, by and for patients.

For the patient, the validation study will take place in 2 phases:

  • A first phase at the time of the consultation (Day 0): response to the questionnaires making up the study, i.e. the short form of the LUTS TCA (appendix 2), then the validated form of the LUTS TCA (22 questions) and finally the PGI (two questions).
  • A second phase, at a distance from the consultation (Day 14 post-consultation): response to the short form of the LUTS TCA (questionnaire handed out at the consultation, accompanied by a stamped envelope for return).
Read the detailed description

For many years, the evaluation of treatments has been a central issue in patient care. The various domains assessed have gradually evolved over time, ranging from satisfaction, improvement and quality of life, to the m ore recent introduction of the Patient Reported Outcome Measure (PROM). These questionnaires or measurement scales (PROMs) focus assessment on the patient and his or her direct experience. Statistical validation of numerous assessment tools has made it possible to quantify objectively many areas of assessment that were initially linked to the patient's feelings, and therefore to their subjectivity. Thus, improvement, quality of life, patient expectations and goal attainment have been the preferred areas for the development of these PROMs.

However, certain areas have been sidelined in the creation of these tools. For example, the constraint of care or the side-effects or negative effects of treatment have been little studied using specific assessment tools.

In the field of neurology or neuro-urology, only a few multidimensional questionnaires take these domains into account. The main one is Qualiveen, which, in addition to quality of life, looks at discomfort, constraint, fear and patient experience. Other questionnaires, less specific in terms of population, enable a multidimensional evaluation of treatments according to 4 domains (efficacy, side effects, ease of use and overall satisfaction) for the Treatment Satisfaction Questionnaire for Medication (TSQM) or 6 domains (side effects, efficacy, practical aspects of drug treatment, effects of drug treatment on daily life, medical follow-up and overall opinion of treatment) for the Treatment Satisfaction with Medicine Questionnaire (SatMed-Q). These 2 multi-dimensional questionnaires do not allow for a targeted assessment of the constraint of care, which represents a much broader domain than the simple side effect or ease of use of a treatment. What's more, a mixed assessment, both positive (improvement, efficacy) and negative (side-effects) on the same questionnaire, may well limit the interpretation of results and patient understanding.

In response to this shortcoming, a specific treatment constraint questionnaire has been developed for neuro-urological treatments in a neurological patient population.

The LUTS-TCA (Lower Urinary Tract Symptoms Treatment Constraints Assessment) was developed in French and statistically validated in 2019. This 22-item questionnaire provides a general assessment of therapeutic constraint (physical, social, psychological, etc.). The "detailed" study of therapeutic stress is an important part of the overall therapeutic assessment of these neurological patients, as therapeutic management is often multiple and complex in terms of treatments, examinations, follow-up and impact on daily life.

The use of specific, validated tools to take account of care constraints is important, and is just as justified as the assessment of satisfaction or therapeutic improvement.

The "detailed" study of care constraints is an important part of the overall therapeutic assessment of these neurological patients, as therapeutic management is often multiple and complex in terms of treatments, examinations, follow-up and impact on daily life.

The use of specific, validated tools to take account of care constraints is important, and is just as justified as the assessment of satisfaction or therapeutic improvement.

One of the most widely used questionnaires for measuring treatment improvement is the Patient Global Impression of Improvment (PGI-I). The PGI-I takes the form of a single question, with a 7-level Likert scale ranging from +3 (much improved) to -3 (not improved at all). These positive and, above all, negative levels can be confused with the care constraint for the negative part of the response mode. To avoid measuring the same thing twice (negative PGI-I and LUTS TCA), it is vital to be able to measure the 2 parameters independently.

The aim of the study is to create a short form of the LUTS TCA in French, in a population of neurological patients.

This short form, which would be easier to use and interpret, would simplify its use in everyday practice. Indeed, a large majority of neuro-urology patients suffer from neurodegenerative or progressive pathologies, marked by significant and disabling physical and psychological fatigue symptoms. Long-form questionnaires, or the addition of multiple assessment questionnaires during a single visit to the department, make overall assessment more complex.

In addition, this short-form questionnaire is presented in a slightly different form to the long-form version, showing several domains of constraint (physical, social, psychological and care system). This classification should simplify the interpretation and understanding of care constraint, by and for patients.

02

Conditions studied

03

In context

Urologic Diseases

193 studies on the registry are indexed under Urologic Diseases; 51 are open to participants now.

This study's planned enrollment of 242 is above the median of 200 across 49 observational studies indexed under Urologic Diseases.

Browse Urologic Diseases studies →

Lead sponsor

Centre Hospitalier de Saint-Denis is the lead sponsor of 42 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients followed in the urology department of the Casanova and Pitié Salepêtrière Hospital

Inclusion criteria

  • Adult patients (age ≥ 18 years)
  • Patients with central or peripheral neurological pathology, followed and managed for vesico-sphincter disorders
  • Patients receiving urinary treatment for more than 3 months
  • No therapeutic modification between D0 and D14 of the questionnaire
  • French-speaking patients (able to read, write and understand French)

Exclusion criteria

Exclusion Criteria:

  • Minor patients (age ≤ 17 years)
  • Patients who have stopped urinary treatment
  • Patients with major cognitive impairment
  • Patients who speak little or no French
  • Patients who refused to participate in research, or who objected to the use of their data for research purposes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
242 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Demographic data

    Age

    Time frame: day 1

  2. Demographic data

    sex

    Time frame: day 1

  3. Mecical history

    The medical history of the patient (treatement, diseases, diagnosis...)

    Time frame: day 1

  4. Treatment(s)

    Treatment(s) taken by the patient (starting date, dosage, end date (if available)...)

    Time frame: day 1

  5. LUTS- TCA Questionnaire (short form)

    This questionnaire only has one question.

    Time frame: day 1

  6. LUTS-TCA questionnaire (original)

    The answers provided by this questionnaire (22 items)

    Time frame: day 1

  7. PGI questionnaire

    The answers of the PGI questionnaire

    Time frame: day 1

07

Study locations

1 of 2 sites recruiting
  • Casanova Hospital
    Saint-Denis, Seine saint denis 93205, France
    Not yet recruiting
  • La pitié salpêtrière
    Paris, 75013, France
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06853366
Lead sponsor
Centre Hospitalier de Saint-Denis
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Feb 20, 2025
Primary completion
Feb 20, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion